In clinical medicine, the plasma FGF23 concentration has been revealed as a valuable disease biomarker [25] which is positively correlated with progression and outcome in chronic kidney disease [26, 27] and further cardiovascular disorders [28–30]. The gene discussed is FGF23; the disease is cardiovascular disorder.